Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.28 USD | -5.31% | +1.66% | -14.57% |
May. 30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
May. 16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 16.54M | Capitalization | 176M |
---|---|---|---|---|---|
Net income 2024 * | -70M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | 66.3M | Net Debt 2025 * | 7.4M | EV / Sales 2025 * | 11.1 x |
P/E ratio 2024 * |
-2.34
x | P/E ratio 2025 * |
-2.78
x | Employees | 84 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on Abeona Therapeutics Inc.
1 day | -5.31% | ||
1 week | +1.66% | ||
Current month | -2.28% | ||
1 month | -10.46% | ||
3 months | -50.69% | ||
6 months | -5.93% | ||
Current year | -14.57% |
Managers | Title | Age | Since |
---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 48 | 21-05-31 |
Michael Amoroso
CHM | Chairman | 46 | 20-07-08 |
Joseph Vazzano
DFI | Director of Finance/CFO | 40 | 22-03-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 56 | 06-02-28 |
Faith Charles
BRD | Director/Board Member | 62 | 21-03-24 |
Leila Alland
BRD | Director/Board Member | 61 | 21-04-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 4.28 | -5.31% | 369,321 |
24-06-05 | 4.52 | +4.39% | 497,901 |
24-06-04 | 4.33 | -4.20% | 405,570 |
24-06-03 | 4.52 | +3.20% | 782,773 |
24-05-31 | 4.38 | +4.04% | 443,061 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.57% | 186M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- ABEO Stock